ARYx is a pharmaceutical company focused on retrometabolic drug designing and improving the safety of oral therapies for chronic diseases.
ARYx is a product-driven pharmaceutical company with leading expertise and significant intellectual property in the area of retrometabolic drug design. They are focused on improving the safety of oral therapies for chronic disease.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Feb 10, 2006 | Series E | $30.40M | 1 | — | — | Detail |
Jun 1, 2004 | Series D | $55M | 3 | Phase4 Ventures | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Phase4 Ventures | — | Series E |
Novel Bioventures | — | Series D |
Jafco Life Science | — | Series D |